Skip to content
MARKETS / NASDAQ / FBIO
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Fortress Biotech, Inc. FBIO

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$61.2M
▲ 11.1% YoY
$6.8M
In brief

What this company does

Fortress works in concert with our extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and financial expertise to help its subsidiaries and partner companies achieve their goals. As of December 31, 2025, we had 78 full-time employees at Fortress and our subsidiaries and partner companies.

Written from the business description in Fortress Biotech, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 61.2M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 61.2 · Net income 6.8
25.0M50.0M-40.0M-80.0M2007201020132016201920222025
Compound annual growth
−4.8%
+6.6%
+53.1%
−3.9%
+22.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−54 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -114.7% · Net -53.7%
-2000%-4000%-6000%2007201020132016201920222025
ROE
FY2025 · ROE 18.8%
-1000%-2000%2007201020132016201920222025

Each USD of equity produced 19 cents of profit this year.

Cash & shareholders
USD 664,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -80.2
-80M-160M2007201020132016201920222025
Net buybacks $M Dividends $M
FY2025 · Dividends 0.7 · Net buybacks —
-20M-40M2019202020212022202320242025

USD 664,000.00 in dividends — 10% of the year's profit went back to shareholders.

Total assetsUSD 185.5M
EquityUSD 49.9M
CashUSD 79.4M
Gross debtUSD 52.4M
Net debtUSD -27.0M
Current ratio2.49×

The company holds more cash than debt.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.10.10.10.10.10.00.00.00.00.00.00.00.0······
Operating income $B−0.1−0.1−0.1−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0··
EBITDA $B−0.1−0.1−0.1−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0··
Income tax $B−0.00.00.00.00.00.00.00.00.00.00.0········
Net income $B0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·−0.1−0.1−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0····
EPS, diluted $−0.07−2.69−8.47−15.97−0.79−0.65−0.73−1.94−1.61−1.38−1.24−0.56−1.22−1.27−5.51−2.24−1.01··
Dividend / sh $···················
Payout %10−2−1−1−1−1−0············
ROE %18.8−203.2−188.7−115.1−61.9−73.5−284.7−309.2−146.9−115.6−76.0−26.9−71.9−134.1−2247.9····
Shares out B0.030.030.020.010.100.090.070.060.050.050.050.050.040.020.020.00···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 17 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image